Analyzing Cost of Revenue: GSK plc and Grifols, S.A.

GSK vs. Grifols: A Decade of Cost Dynamics

__timestamp	GSK plc	Grifols, S.A.
Wednesday, January 1, 2014	7323000000	1656170000
Thursday, January 1, 2015	8853000000	2003565000
Friday, January 1, 2016	9290000000	2137539000
Sunday, January 1, 2017	10342000000	2166062000
Monday, January 1, 2018	10241000000	2437164000
Tuesday, January 1, 2019	11863000000	2757459000
Wednesday, January 1, 2020	11704000000	3084873000
Friday, January 1, 2021	11603000000	2970522000
Saturday, January 1, 2022	9554000000	3832437000
Sunday, January 1, 2023	8565000000	4269276000

Unleashing the power of data

Analyzing Cost of Revenue: GSK plc vs. Grifols, S.A.

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. This analysis delves into the cost of revenue for two major players: GSK plc and Grifols, S.A., from 2014 to 2023. Over this period, GSK's cost of revenue peaked in 2019, reaching approximately 12% higher than its 2014 value. However, by 2023, it had decreased by around 28% from its peak. In contrast, Grifols, S.A. exhibited a steady upward trend, with its cost of revenue increasing by nearly 158% over the same period. This divergence highlights GSK's strategic cost management and Grifols' expansion efforts. As the pharmaceutical landscape continues to shift, these insights provide a window into the financial strategies of industry leaders.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025